文献速递艾滋病与性传播感染

非M组HIV-1对整合酶链转移抑制剂的表型敏感性

HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

研究评估了39株非M组HIV-1(O、N、P组)临床株对拉替拉韦、埃替拉韦和多替拉韦的天然表型敏感性,并分析整合酶基因多态性。结果显示三种药物IC50相似,拉替拉韦和多替拉韦折叠变化<2.5,埃替拉韦分布不均,6株(15%)折叠变化>10。非M株整合酶高度多态但无主要基因型影响,部分突变可能与埃替拉韦高折叠变化相关。

要点

  • 非M组HIV-1对拉替拉韦和多替拉韦天然敏感,折叠变化<2.5。
  • 埃替拉韦对部分非M株折叠变化>10(6/39株,15%),需关注。
  • 整合酶多态性高但无主要耐药突变影响,临床数据待验证。

核心结论

  • 非M组HIV-1整体对当前三种INSTIs敏感,但埃替拉韦对部分株高折叠变化的影响需进一步探索。

研究设计与样本

  • 研究纳入36株HIV-1/O、2株HIV-1/N和1株HIV-1/P临床株,外加1株HIV-1/M参考株,共39株非M组和1株M组。

主要发现

  • 三种药物IC50结果相似,基于HIV-1/M参考株,拉替拉韦和多替拉韦折叠变化<2.5。
  • 埃替拉韦折叠变化分布不均,6株(15%)折叠变化>10。
  • 非M株整合酶序列高度多态,无主要基因型影响,但发现可能与埃替拉韦高折叠变化相关的突变。

关键数值与推荐

  • 拉替拉韦和多替拉韦折叠变化<2.5(基于HIV-1/M参考株)。
  • 埃替拉韦对6株(15%)非M株折叠变化>10。

临床怎么用

  • 非M组HIV-1感染者使用拉替拉韦或多替拉韦可能有效,埃替拉韦需谨慎并考虑表型检测。

局限性

  • 需临床数据确认表型结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine natural phenotypic susceptibility of non-group M HIV-1 to integrase strand transfer inhibitors (INSTIs) in a large panel of 39 clinical strains from groups O, N and P and to identify genotypic polymorphisms according to susceptibility levels. METHODS: Susceptibility to raltegravir, elvitegravir and dolutegravir was evaluated in 36 HIV-1/O, 2 HIV-1/N and 1 HIV-1/P strains plus an HIV-1/M reference strain. IC50 values were determined after 3 days, and fold changes (FCs) were calculated relative to the HIV-1/M strain. Genotypic polymorphism was determined by amplification of codons 19-263 of the integrase; the natural occurrence of resistance-associated mutations was analysed using the main resistance algorithms and the IAS-USA list. VESPA analysis of the strain sequences was used to determine a signature pattern associated with higher FC. RESULTS: Similar IC50 results were observed for the three drugs. Based on the value for the HIV-1/M reference strain, the data showed FC values <2.5 for raltegravir and dolutegravir, whereas the distribution for elvitegravir was heterogeneous, with FC > 10 for six strains (15%). Analysis of the non-M integrase sequences showed a high level of polymorphism without a major genotypic impact; it also revealed mutations that may be associated with the highest FC values obtained for elvitegravir. CONCLUSIONS: Our phenotypic data showed that non-M strains are globally susceptible to the three currently used INSTIs, but the impact of the high FC values observed for some strains with elvitegravir needs to be explored. Clinical data are now needed to confirm these phenotypic results.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Alessandri-Gradt E, Collin G, Tourneroche A, et al. HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors. J Antimicrob Chemother. 2017. PMID: 28859447. doi:10.1093/jac/dkx190

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。